Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of Universal CAR-T Cells (BRL-301) in the Treatment of Relapse or Refractory Autoimmune Diseases

NCT05859997 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT05859997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of Universal CAR-T Cells (BRL-301) in the Treatment of Relapse or Refractory Autoimmune Diseases
Lead sponsor
Bioray Laboratories
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
May 17, 2023
Completion date
May 27, 2025
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated systemic vasculitis, antiphospholipid syndrome, inflammatory myopathy, sjogren's syndrome, systemic lupus erythematosus (sle), systemic sclerosis